Mechanism of Action
GLP-1 Receptor Signaling
GLP-1 binds GLP-1R, a class B Gs-coupled GPCR expressed in pancreatic beta cells, gut, heart, kidney, lung, and throughout the brain. Receptor activation elevates cAMP and activates PKA, which potentiates glucose-stimulated insulin secretion (GSIS) without causing insulin release at euglycemia, the critical safety feature of incretin-based therapy. GLP-1R also couples to Epac2, beta-arrestins, and PI3K, producing diverse downstream effects.
Incretin Effect and Pancreatic Actions
The incretin effect, the greater insulin secretion after oral versus IV glucose - accounts for 50-70% of post-prandial insulin release and is significantly impaired in type 2 diabetes. GLP-1 is responsible for approximately two-thirds of the incretin effect. Beyond insulin secretion, GLP-1 suppresses glucagon from alpha cells, delays gastric emptying to moderate post-prandial glucose excursions, and promotes beta cell proliferation while reducing apoptosis.
CNS and Cardiovascular Effects
GLP-1R in the hypothalamus (arcuate nucleus, PVN) and brainstem (nucleus tractus solitarius) mediate appetite suppression and satiety signaling. These central effects explain the weight loss produced by GLP-1 analogs that goes beyond blood glucose lowering. GLP-1R in the heart and vasculature mediates cardioprotective effects including reduced infarct size, improved cardiac function, and anti-inflammatory vascular effects validated in multiple cardiovascular outcome trials.
Research Summary
Type 2 Diabetes
HumanGLP-1 analog therapy (liraglutide, semaglutide, dulaglutide, exenatide) reduces HbA1c by 1-2%, promotes weight loss, and demonstrates cardiovascular and renal benefits beyond glycemic control in the LEADER, SUSTAIN-6, and REWIND trials. The glucose-dependent mechanism of action eliminates hypoglycemia risk, a major advance over sulfonylureas and insulin.
Obesity
HumanAt higher doses than used for diabetes, GLP-1 analogs produce substantial weight loss: semaglutide 2.4 mg weekly (Wegovy) produced 14-15% body weight reduction in the STEP trials, comparable to bariatric surgery outcomes for some patients. The SURMOUNT trials showed tirzepatide (GLP-1/GIP dual agonist) achieving up to 22% weight loss, the highest recorded for a pharmaceutical.
Neuroprotection and Alzheimer's
HumanGLP-1R is expressed throughout the brain and GLP-1 analogs cross the blood-brain barrier. Phase II trials of liraglutide in Parkinson's disease showed slower motor decline. GLP-1R agonists are in Phase II/III trials for Alzheimer's disease based on preclinical neuroprotective data. Epidemiological studies find GLP-1 analog users have lower dementia incidence.
Calculate your GLP-1 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Incretin physiology research | 0.75-1.5 pmol/kg/min | IV infusion during meal study | Intravenous |
| Beta cell function testing | 0.5 nmol IV bolus | Single dose before glucose clamp | Intravenous |
Native GLP-1 is a research tool due to its 2-minute half-life. Clinical use relies on DPP-4-resistant analogs (liraglutide, semaglutide) or DPP-4 inhibitors that prolong endogenous GLP-1 activity.
Interactions
Safety Profile
Native GLP-1 is an endogenous hormone with an inherently favorable safety profile. Its glucose-dependent action on insulin secretion means hypoglycemia does not occur with native GLP-1 at physiological doses. GLP-1 analogs extensively characterized in clinical trials show nausea, vomiting, and diarrhea as the most common side effects, typically dose-dependent and transient. Rare risk of pancreatitis, gallstones (from reduced gallbladder motility), and potential thyroid C-cell concerns with long-acting analogs in rodents (not confirmed in humans).
References
- [1]Mojsov S, et al. Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest. 1987;79(2):616-619.
- [2]Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756.
- [3]Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844.